Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: a randomized, crossover, multicentre study in patients with Parkinson's disease

被引：0

作者：

Marttila, R. ^{[1
]}

Kaasinen, V. ^{[1
]}

Hartikainen, P. ^{[2
]}

Lyytinen, J. ^{[3
]}

Kaakkola, S. ^{[3
]}

Hanninen, J. ^{[4
,5
]}

Korpela, K. ^{[4
,5
]}

Laapas, K. ^{[4
,5
]}

Kuoppamaki, M. ^{[1
,4
,5
]}

Ellmen, J. ^{[4
,5
]}

机构：

[1] Turku Univ Hosp, Dept Neurol, FIN-20520 Turku, Finland

[2] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland

[3] Helsinki Univ Hosp, Dept Neurol, Helsinki, Finland

[4] Orion Phama, Turku, Finland

[5] Orion Pharma, Espoo, Finland

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2008年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：115 / 115

页数：1

共 50 条

[41] Significant benefits of the direct switch from conventional levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with early wearing-off
Eggert, K.
Oertel, W.
Skogar, O.
Amar, K.
Luotonen, L.
Nissinen, H.
EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 125 - 125
[42] An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson’s disease patients experiencing wearing-off
W. Koller
M. Guarnieri
J. Hubble
A. L. Rabinowicz
D. Silver
Journal of Neural Transmission, 2005, 112 : 221 - 230
[43] Effect of carbidopa, entacapone and levodopa at bed time on sleep quality in Parkinson's disease compared to levodopa and carbidopa-CR
Ma, H. I.
Baik, J. S.
Kang, S. Y.
Kim, J. W.
Kim, Y. J.
MOVEMENT DISORDERS, 2012, 27 : S219 - S219
[44] Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo*) compared to standard care in UK Parkinson's disease patients with wearing-off
Findley, LJ
Lees, A
Apajasalo, M
Pitkänen, A
Turunen, H
CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (07) : 1005 - 1014
[45] An open-label evaluation of the tolerability and safety of Stalevo® (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off
Koller, W
Guarnieri, M
Hubble, J
Rabinowicz, AL
Silver, D
JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (02) : 221 - 230
[46] Stalevo (levodopa/carbidopa/entacapon) - a new generation drug in the treatment of Parkinson's disease
Fedorova, N. V.
Levin, O. S.
Smolentseva, I. G.
Kulua, T. K.
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2006, 106 (09) : 39 - 46
[47] North American Subgroup Analysis of the FIRST-STEP Trial of Levodopa/Carbidopa/Entacapone and Levodopa/Carbidopa in Patients with Early Parkinson's Disease
Silver, Dee
McCague, Kevin
Somogyi, Monique
Hauser, Robert
NEUROLOGY, 2009, 72 (11) : A318 - A319
[48] Quality of Life in Early Parkinson's Disease Treated with Levodopa/Carbidopa/Entacapone
Fung, Victor S. C.
Herawati, Lilie
Wan, Ying
MOVEMENT DISORDERS, 2009, 24 (01) : 25 - 31
[49] Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease
Poulopoulos, Markos
Waters, Cheryl
CORE EVIDENCE, 2010, 5 : 1 - 10
[50] Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
Mikko Kuoppamäki
Mika Leinonen
Werner Poewe
Journal of Neural Transmission, 2015, 122 : 1709 - 1714

← 1 2 3 4 5 →